Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry
Identifieur interne : 002485 ( Ncbi/Curation ); précédent : 002484; suivant : 002486Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry
Auteurs : Miyuki Kawase [Japon] ; Kazuya Shirato [Japon] ; Lia Van Der Hoek [Pays-Bas] ; Fumihiro Taguchi [Japon] ; Shutoku Matsuyama [Japon]Source :
- Journal of Virology [ 0022-538X ] ; 2012.
Descripteurs français
- KwdFr :
- Bronches (cytologie), Bronches (virologie), Cellules épithéliales (), Cellules épithéliales (virologie), Humains, Inhibiteurs de la cystéine protéinase (pharmacologie), Inhibiteurs de la sérine protéinase (pharmacologie), Pénétration virale (), Régulation négative (), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (), Virus du SRAS (physiologie).
- MESH :
- cytologie : Bronches.
- pharmacologie : Inhibiteurs de la cystéine protéinase, Inhibiteurs de la sérine protéinase.
- physiologie : Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- virologie : Bronches, Cellules épithéliales, Syndrome respiratoire aigu sévère.
- Cellules épithéliales, Humains, Pénétration virale, Régulation négative, Virus du SRAS.
English descriptors
- KwdEn :
- Bronchi (cytology), Bronchi (virology), Cysteine Proteinase Inhibitors (pharmacology), Down-Regulation (drug effects), Epithelial Cells (drug effects), Epithelial Cells (virology), Humans, SARS Virus (drug effects), SARS Virus (physiology), Serine Proteinase Inhibitors (pharmacology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Virus Internalization (drug effects).
- MESH :
- chemical , pharmacology : Cysteine Proteinase Inhibitors, Serine Proteinase Inhibitors.
- cytology : Bronchi.
- drug effects : Down-Regulation, Epithelial Cells, SARS Virus, Virus Internalization.
- drug therapy : Severe Acute Respiratory Syndrome.
- physiology : SARS Virus.
- virology : Bronchi, Epithelial Cells, Severe Acute Respiratory Syndrome.
- Humans.
Abstract
The type II transmembrane protease TMPRSS2 activates the spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) on the cell surface following receptor binding during viral entry into cells. In the absence of TMPRSS2, SARS-CoV achieves cell entry via an endosomal pathway in which cathepsin L may play an important role, i.e., the activation of spike protein fusogenicity. This study shows that a commercial serine protease inhibitor (camostat) partially blocked infection by SARS-CoV and human coronavirus NL63 (HCoV-NL63) in HeLa cells expressing the receptor angiotensin-converting enzyme 2 (ACE2) and TMPRSS2. Simultaneous treatment of the cells with camostat and EST [(23,25)
Url:
DOI: 10.1128/JVI.00094-12
PubMed: 22496216
PubMed Central: 3393535
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C70
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000C70
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000A29
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001376
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001376
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001278
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002485
Links to Exploration step
PMC:3393535Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry</title><author><name sortKey="Kawase, Miyuki" sort="Kawase, Miyuki" uniqKey="Kawase M" first="Miyuki" last="Kawase">Miyuki Kawase</name><affiliation wicri:level="3"><nlm:aff id="aff1">Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo, Japan</nlm:aff><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Shirato, Kazuya" sort="Shirato, Kazuya" uniqKey="Shirato K" first="Kazuya" last="Shirato">Kazuya Shirato</name><affiliation wicri:level="3"><nlm:aff id="aff1">Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo, Japan</nlm:aff><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Van Der Hoek, Lia" sort="Van Der Hoek, Lia" uniqKey="Van Der Hoek L" first="Lia" last="Van Der Hoek">Lia Van Der Hoek</name><affiliation wicri:level="4"><nlm:aff id="aff3">Department of Medical Microbiology, University of Amsterdam, Faculty of Earth and Life Sciences, Amsterdam, The Netherlands</nlm:aff><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Microbiology, University of Amsterdam, Faculty of Earth and Life Sciences, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName><orgName type="university">Université d'Amsterdam</orgName></affiliation></author><author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name><affiliation wicri:level="3"><nlm:aff id="aff2">Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Kyonan-cho, Musashino, Tokyo, Japan</nlm:aff><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Kyonan-cho, Musashino, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Matsuyama, Shutoku" sort="Matsuyama, Shutoku" uniqKey="Matsuyama S" first="Shutoku" last="Matsuyama">Shutoku Matsuyama</name><affiliation wicri:level="3"><nlm:aff id="aff1">Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo, Japan</nlm:aff><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22496216</idno><idno type="pmc">3393535</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393535</idno><idno type="RBID">PMC:3393535</idno><idno type="doi">10.1128/JVI.00094-12</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000C70</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000C70</idno><idno type="wicri:Area/Pmc/Curation">000C70</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000C70</idno><idno type="wicri:Area/Pmc/Checkpoint">000A29</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A29</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:22496216</idno><idno type="wicri:Area/PubMed/Corpus">001376</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001376</idno><idno type="wicri:Area/PubMed/Curation">001376</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001376</idno><idno type="wicri:Area/PubMed/Checkpoint">001278</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001278</idno><idno type="wicri:Area/Ncbi/Merge">002485</idno><idno type="wicri:Area/Ncbi/Curation">002485</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry</title><author><name sortKey="Kawase, Miyuki" sort="Kawase, Miyuki" uniqKey="Kawase M" first="Miyuki" last="Kawase">Miyuki Kawase</name><affiliation wicri:level="3"><nlm:aff id="aff1">Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo, Japan</nlm:aff><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Shirato, Kazuya" sort="Shirato, Kazuya" uniqKey="Shirato K" first="Kazuya" last="Shirato">Kazuya Shirato</name><affiliation wicri:level="3"><nlm:aff id="aff1">Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo, Japan</nlm:aff><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Van Der Hoek, Lia" sort="Van Der Hoek, Lia" uniqKey="Van Der Hoek L" first="Lia" last="Van Der Hoek">Lia Van Der Hoek</name><affiliation wicri:level="4"><nlm:aff id="aff3">Department of Medical Microbiology, University of Amsterdam, Faculty of Earth and Life Sciences, Amsterdam, The Netherlands</nlm:aff><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Microbiology, University of Amsterdam, Faculty of Earth and Life Sciences, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName><orgName type="university">Université d'Amsterdam</orgName></affiliation></author><author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name><affiliation wicri:level="3"><nlm:aff id="aff2">Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Kyonan-cho, Musashino, Tokyo, Japan</nlm:aff><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Kyonan-cho, Musashino, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Matsuyama, Shutoku" sort="Matsuyama, Shutoku" uniqKey="Matsuyama S" first="Shutoku" last="Matsuyama">Shutoku Matsuyama</name><affiliation wicri:level="3"><nlm:aff id="aff1">Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo, Japan</nlm:aff><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology III, National Institute of Infectious Diseases, Murayama Branch, Gakuen Musashi-Murayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><series><title level="j">Journal of Virology</title><idno type="ISSN">0022-538X</idno><idno type="eISSN">1098-5514</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bronchi (cytology)</term><term>Bronchi (virology)</term><term>Cysteine Proteinase Inhibitors (pharmacology)</term><term>Down-Regulation (drug effects)</term><term>Epithelial Cells (drug effects)</term><term>Epithelial Cells (virology)</term><term>Humans</term><term>SARS Virus (drug effects)</term><term>SARS Virus (physiology)</term><term>Serine Proteinase Inhibitors (pharmacology)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Virus Internalization (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Bronches (cytologie)</term><term>Bronches (virologie)</term><term>Cellules épithéliales ()</term><term>Cellules épithéliales (virologie)</term><term>Humains</term><term>Inhibiteurs de la cystéine protéinase (pharmacologie)</term><term>Inhibiteurs de la sérine protéinase (pharmacologie)</term><term>Pénétration virale ()</term><term>Régulation négative ()</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Cysteine Proteinase Inhibitors</term><term>Serine Proteinase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Bronches</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Bronchi</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Down-Regulation</term><term>Epithelial Cells</term><term>SARS Virus</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de la cystéine protéinase</term><term>Inhibiteurs de la sérine protéinase</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Bronches</term><term>Cellules épithéliales</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Bronchi</term><term>Epithelial Cells</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cellules épithéliales</term><term>Humains</term><term>Pénétration virale</term><term>Régulation négative</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The type II transmembrane protease TMPRSS2 activates the spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) on the cell surface following receptor binding during viral entry into cells. In the absence of TMPRSS2, SARS-CoV achieves cell entry via an endosomal pathway in which cathepsin L may play an important role, i.e., the activation of spike protein fusogenicity. This study shows that a commercial serine protease inhibitor (camostat) partially blocked infection by SARS-CoV and human coronavirus NL63 (HCoV-NL63) in HeLa cells expressing the receptor angiotensin-converting enzyme 2 (ACE2) and TMPRSS2. Simultaneous treatment of the cells with camostat and EST [(23,25)<italic>trans</italic>-epoxysuccinyl-<sc>l</sc>-leucylamindo-3-methylbutane ethyl ester], a cathepsin inhibitor, efficiently prevented both cell entry and the multistep growth of SARS-CoV in human Calu-3 airway epithelial cells. This efficient inhibition could be attributed to the dual blockade of entry from the cell surface and through the endosomal pathway. These observations suggest camostat as a candidate antiviral drug to prevent or depress TMPRSS2-dependent infection by SARS-CoV.</p></div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002485 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002485 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= PMC:3393535
|texte= Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:22496216" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |